Calidi Biotherapeutics, founded in 2015, is a clinical-stage biotechnology company that strives to pioneer advancements in the field of oncolytic virus-based immunotherapies. The company's mission is to transform the cancer treatment landscape by unlocking the power of the immune system. Calidi Biotherapeutics' novel therapies aim to improve patient survival and quality of life by selectively killing cancer cells while activating immune responses. The company is headquartered in San Diego, California.
Calidi Biotherapeutics does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.
The stock price for Calidi Biotherapeutics will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).
Calidi Biotherapeutics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own Calidi Biotherapeutics pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
Calidi Biotherapeutics is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.